BioLine RX Ltd (BLRX) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.108x

Based on the latest financial reports, BioLine RX Ltd (BLRX) has a cash flow conversion efficiency ratio of -0.108x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-2.11 Million ≈ $-5.65K USD) by net assets (ILA19.53 Million ≈ $52.37K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BioLine RX Ltd net asset quality index to measure how much of total assets are equity-financed.

BioLine RX Ltd - Cash Flow Conversion Efficiency Trend (2010–2024)

This chart illustrates how BioLine RX Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BLRX operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

BioLine RX Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of BioLine RX Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Nusa Palapa Gemilang PT Tbk JK:NPGF	0.084x
INNEOVA Holdings Limited NASDAQ:INEO	0.954x
GPM Metals Inc V:GPM	-0.638x
Tectona TA:TECT	-0.123x
Star Diamond Corp TO:DIAM	-0.102x
Arts-Way Manufacturing Co Inc NASDAQ:ARTW	0.011x
Elementis PLC LSE:ELM	0.069x
Mustika Ratu Tbk JK:MRAT	0.009x

Annual Cash Flow Conversion Efficiency for BioLine RX Ltd (2010–2024)

The table below shows the annual cash flow conversion efficiency of BioLine RX Ltd from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of BioLine RX Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	ILA13.46 Million ≈ $36.09K	ILA-43.87 Million ≈ $-117.62K	-3.259x	-90.63%
2023-12-31	ILA13.22 Million ≈ $35.45K	ILA-22.61 Million ≈ $-60.61K	-1.710x	-231.27%
2022-12-31	ILA50.84 Million ≈ $136.30K	ILA-26.24 Million ≈ $-70.35K	-0.516x	-49.07%
2021-12-31	ILA68.09 Million ≈ $182.54K	ILA-23.57 Million ≈ $-63.20K	-0.346x	+67.13%
2020-12-31	ILA22.03 Million ≈ $59.06K	ILA-23.21 Million ≈ $-62.21K	-1.053x	-55.13%
2019-12-31	ILA33.38 Million ≈ $89.49K	ILA-22.67 Million ≈ $-60.77K	-0.679x	-15.98%
2018-12-31	ILA41.32 Million ≈ $110.78K	ILA-24.19 Million ≈ $-64.86K	-0.585x	-50.68%
2017-12-31	ILA52.88 Million ≈ $141.77K	ILA-20.55 Million ≈ $-55.09K	-0.389x	+6.22%
2016-12-31	ILA35.03 Million ≈ $93.91K	ILA-14.51 Million ≈ $-38.91K	-0.414x	-39.23%
2015-12-31	ILA47.61 Million ≈ $127.64K	ILA-14.17 Million ≈ $-37.98K	-0.298x	+34.72%
2014-12-31	ILA31.77 Million ≈ $85.16K	ILA-14.48 Million ≈ $-38.82K	-0.456x	+73.68%
2013-12-31	ILA11.68 Million ≈ $31.32K	ILA-20.23 Million ≈ $-54.25K	-1.732x	-28.90%
2012-12-31	ILA14.97 Million ≈ $40.14K	ILA-20.11 Million ≈ $-53.93K	-1.344x	-169.77%
2011-12-31	ILA22.53 Million ≈ $60.41K	ILA-11.22 Million ≈ $-30.09K	-0.498x	-673.33%
2010-12-31	ILA131.96 Million ≈ $353.78K	ILA11.46 Million ≈ $30.73K	0.087x	--

About BioLine RX Ltd

TA:BLRX Israel Biotechnology

Market Cap

$11.20 Million

ILA4.18 Billion ILA

Market Cap Rank

#26779 Global

#385 in Israel

Share Price

ILA1.60

Change (1 day)

+6.67%

52-Week Range

ILA1.20 - ILA2.60

All Time High

ILA618.30